Literature DB >> 16697104

Stimulatory effects of lipopolysaccharide on endothelial cell activin and follistatin.

Kathryn M Wilson1, A Ian Smith, David J Phillips.   

Abstract

Activin A and its binding protein, follistatin, are released into the circulation following acute systemic inflammation. In this study, we determined the activin and follistatin response of ovine aortic endothelial cells to lipopolysaccharide (LPS). Exposure to LPS for 1h, mimicking a transient inflammatory event, elicited significant increases in activin betaA subunit mRNA or activin A release, with larger, more prolonged increases evident with continuous exposure. On the other hand, follistatin increases were only evident with prolonged exposure to LPS and following increases in activin A release. While cell-associated activin A increased with LPS exposure, levels were lower than those secreted, whereas the opposite was apparent for follistatin. In summary, our findings suggest that vascular endothelial cells, while capable of releasing activin A and follistatin following inflammatory stimulation, are unlikely to be responsible for the rapid release of activin A in vivo following inflammatory challenge.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16697104     DOI: 10.1016/j.mce.2006.03.041

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  10 in total

1.  Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia.

Authors:  Kristian L Jones; Ashley Mansell; Shane Patella; Bernadette J Scott; Mark P Hedger; David M de Kretser; David J Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

Review 2.  Immunoregulation by members of the TGFβ superfamily.

Authors:  WanJun Chen; Peter Ten Dijke
Journal:  Nat Rev Immunol       Date:  2016-11-25       Impact factor: 53.106

3.  Effects of chronic hepatitis C genotype 1 and 4 on serum activins and follistatin in treatment naïve patients and their correlations with interleukin-6, tumour necrosis factor-α, viral load and liver damage.

Authors:  Bassem Refaat; Ahmed Mohammed Ashshi; Adel Galal El-Shemi; Adnan AlZanbagi
Journal:  Clin Exp Med       Date:  2014-06-13       Impact factor: 3.984

Review 4.  The biology of activin: recent advances in structure, regulation and function.

Authors:  Yin Xia; Alan L Schneyer
Journal:  J Endocrinol       Date:  2009-03-09       Impact factor: 4.286

5.  Female infertility and disrupted angiogenesis are actions of specific follistatin isoforms.

Authors:  Shyr-Yeu Lin; Rebecca G Craythorn; Anne E O'Connor; Martin M Matzuk; Jane E Girling; John R Morrison; David M de Kretser
Journal:  Mol Endocrinol       Date:  2007-10-11

6.  The effects of pegylated interferon-α and ribavirin on liver and serum concentrations of activin-A and follistatin in normal Wistar rat: a preliminary report.

Authors:  Bassem Refaat; Adel Galal El-Shemi; Ahmed Mohammed Ashshi
Journal:  BMC Res Notes       Date:  2015-06-26

Review 7.  Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy.

Authors:  Bassem Refaat; Ahmed Mohamed Ashshi; Adel Galal El-Shemi; Esam Azhar
Journal:  Mediators Inflamm       Date:  2015-04-19       Impact factor: 4.711

8.  Pegylated Interferon-α Modulates Liver Concentrations of Activin-A and Its Related Proteins in Normal Wistar Rat.

Authors:  Bassem Refaat; Adel Galal El-Shemi; Ahmed Mohamed Ashshi; Elaf Wael Mahamid; Noha Mohammed Al-Qadi
Journal:  Mediators Inflamm       Date:  2015-07-06       Impact factor: 4.711

9.  Activin A regulates activation of mouse neutrophils by Smad3 signalling.

Authors:  Yan Qi; Jingyan Ge; Chunhui Ma; Na Wu; Xueling Cui; Zhonghui Liu
Journal:  Open Biol       Date:  2017-05       Impact factor: 6.411

Review 10.  Activin, neutrophils, and inflammation: just coincidence?

Authors:  Paschalis Sideras; Eirini Apostolou; Athanasios Stavropoulos; Alexandros Sountoulidis; Arianna Gavriil; Anastasia Apostolidou; Evangelos Andreakos
Journal:  Semin Immunopathol       Date:  2013-02-06       Impact factor: 9.623

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.